Hot topics in tetralogy of Fallot
Juan Villafañe, Jeffrey A Feinstein, Kathy J Jenkins, Robert N Vincent, Edward P Walsh, Anne M Dubin, Tal Geva, Jeffrey A Towbin, Meryl S Cohen, Charles Fraser, Joseph Dearani, David Rosenthal, Beth Kaufman, Thomas P Graham Jr, Adult Congenital and Pediatric Cardiology Section, American College of Cardiology, Juan Villafañe, Jeffrey A Feinstein, Kathy J Jenkins, Robert N Vincent, Edward P Walsh, Anne M Dubin, Tal Geva, Jeffrey A Towbin, Meryl S Cohen, Charles Fraser, Joseph Dearani, David Rosenthal, Beth Kaufman, Thomas P Graham Jr, Adult Congenital and Pediatric Cardiology Section, American College of Cardiology
Abstract
Tetralogy of Fallot (TOF) is the most common cyanotic congenital heart defect. We explore "hot topics" to highlight areas of emerging science for clinicians and scientists in moving toward a better understanding of the long-term management of patients with repaired TOF. From a genetic perspective, the etiology of TOF is multifactorial, with a familial recurrence risk of 3%. Cardiac magnetic resonance is the gold standard assessment tool based on its superior imaging of the right ventricular (RV) outflow tract, pulmonary arteries, aorta, and aortopulmonary collaterals, and on its ability to quantify biventricular size and function, pulmonary regurgitation (PR), and myocardial viability. Atrial re-entrant tachycardia will develop in more than 30% of patients, and high-grade ventricular arrhythmias will be seen in about 10% of patients. The overall incidence of sudden cardiac death is estimated at 0.2%/yr. Risk stratification, even with electrophysiologic testing and cardiac magnetic resonance, remains imperfect. Drug therapy has largely been abandoned, and defibrillator placement, despite its high risks for complications and inappropriate discharges, is often recommended for patients at higher risk. Definitive information about optimal surgical strategies for primary repair to preserve RV function, reduce arrhythmia, and optimize functional status is lacking. Post-operative lesions are often amenable to transcatheter intervention. In selected cases, PR may be treated with transcatheter valve insertion. Ongoing surveillance of RV function is a crucial component of clinical assessment. Except for resynchronization with biventricular pacing, no medical therapies have been shown to be effective after RV dysfunction occurs. In patients with significant PR with RV dilation, optimal timing of pulmonary valve replacement remains uncertain, although accepted criteria are emerging.
Keywords: B-type natriuretic peptide; BNP; CMR; ECHO; EF; ICD; LV; NYHA; New York Heart Association; PR; PVR; RV; SCD; TAPSE; TOF; arrhythmias; cardiac magnetic resonance; echocardiography; ejection fraction; imaging; implantable cardioverter-defibrillator; left ventricular; pulmonary regurgitation; pulmonary valve replacement; right ventricular; sudden cardiac death; tetralogy of Fallot; tricuspid annular plane systolic excursion; ventricular function and heart failure.
Copyright © 2013 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Source: PubMed